New drug therapies on the horizon for IBD

Digestive Diseases

Volumn 30, Issue SUPPL. 1, 2012, Pages 100-105

  Perrier, Clmentine ^a   Rutgeerts, Paul ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b University Ziekenhuis Gasthuisberg   (Belgium)

Author keywords

Adhesion molecules; Biological therapy; Crohn's disease; Interleukins; Janus kinase; Ulcerative colitis

Indexed keywords

ADALIMUMAB; BRIAKINUMAB; CERTOLIZUMAB PEGOL; ETROLIZUMAB; GAMMA INTERFERON; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; JANUS KINASE; NATALIZUMAB; PALCEBO; RECOMBINANT TUMOR NECROSIS FACTOR; TOFACITINIB; TUMOR NECROSIS FACTOR KINOID; UNCLASSIFIED DRUG; USTEKINUMAB; VEDOLIZUMAB;

ACTIVE IMMUNIZATION; ANKYLOSING SPONDYLITIS; ANTIBODY RESPONSE; ARTICLE; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG EFFICACY; ENTERITIS; HEMATOLOGICAL PARAMETERS; HUMAN; IN VIVO STUDY; INTESTINE INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL ADHESION MOLECULES; HUMANS; IMMUNIZATION; INFLAMMATORY BOWEL DISEASES; PYRIMIDINES; PYRROLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867693650     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000341133     Document Type: Article

References (29)

1. Rutgeerts P, Vermeire S, van Assche G: Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-1197.
2. Sandborn W, Feagan B, Marano C, et al: A phase 2/3 multicenter, randomized, placebocontrolled, double-blind study to evaluate the safety and efficacy of golimumab induction therapy, administered subcutaneously, in patients with moderately to severely active ulcerative colitis: Results from the PURSUIT SC study. DDW 2012, abstract 943d.
3. Vandepapeliere P, Malan F, Rogler G, et al: Safety, immunogenicity and clinical phase I-II results of TNF-Kinoid immunotherapeutic in Crohn's disease patients. DDW 2011, abstract 773.
4. Delavallee L, Semerano L, Assier E, et al: Active immunization to tumor necrosis factoralpha is effective in treating chronic established inflammatory disease: A long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009; 11:R195.
5. Sandborn WJ, Feagan BG, Fedorak RN, et al: A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-1141.
6. Mannon PJ, Fuss IJ, Mayer L, et al: Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-2079. (Pubitemid 39482500)
7. Panaccione R, Gamelli A, Sandborn W, Al E: Briakinumab (ABT874) for treatment of Crohn's disease (CD). UEGW 2010, abstract OP051D.
8. Sandborn W, Gasink C, Gao L, et al: A multicenter, randomized double-blind placebocontrolled phase 2b study of ustekinumab, a human monoclonal antibody to IL-12/23 p40 in patients with moderately to severely active Crohn's disease: Results through week 22 from the Certifi trial. DDW 2011;A-145: 592.
9. Ghosh S, Goldin E, Gordon FH, et al: Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32. (Pubitemid 36026343)
10. Sandborn WJ, Colombel JF, Enns R, et al: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925. (Pubitemid 41565956)
11. Targan SR, Feagan BG, Fedorak RN, et al: Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-1683. (Pubitemid 46695722)
12. Kleinschmidt-Demasters BK, Tyler KI: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374.
13. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-381. (Pubitemid 41132342)
14. van Assche G, van Ranst M, Sciot R, et al: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353: 362-368. (Pubitemid 41132340)
15. Feagan BG, Greenberg GR, Wild G, et al: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352: 2499-2507. (Pubitemid 41007865)
16. Parikh A, Leach T, Wyant T, et al: Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2011, E-pub ahead of print.
17. Feagan BG, Greenberg GR, Wild G, et al: Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6: 1370-1377.
18. Feagan B, Rutgeerts P, Sands B, et al: Vedolizumab induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 Trial. DDW 2012, abstract 943b.
19. Rutgeerts PFR, Hommes DW, Sturm A, Baumgart DC, Bressler B, Schreiber S, Mansfield JC, Williams M, Tang M, Visich J, Wei X, Keir M, Luca D, Danilenko D, Egen JG, O'Byrne S: A randomized phase I study of etrolizumab (rhuMAb 7) in moderate to severe ulcerative colitis. Gut 2012, E-pub ahead of print.
20. Vermeire S, Ghosh S, Panes J, et al: The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: A randomised study. Gut 2011; 60: 1068-1075.
21. Perrier C, Rutgeerts P: Cytokine blockade in inflammatory bowel diseases. Immunotherapy 2011; 3: 1341-1352.
22. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC: Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol 2007; 44: 2497-2506. (Pubitemid 46240311)
23. Riese RJ, Krishnaswami S, Kremer J: Inhibition of JAK kinases in patients with rheumatoid arthritis: Scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010; 24: 513-526.
24. Sandborn W, Ghosh S, Panes J, et al: Phase 2 study of CP-690, 550, an oral Janus kinase inhibitor, in active ulcerative colitis. DDW 2011, abstract 594.
25. Sandborn W, Ghosh S, Panes J, Vranic I, Spanton J, Niezychowski W: Phase 2 randomized study of CP-690,550, an oral Janus kinase inhibitor, in active Crohn's disease. DDW 2011, abstract 745.
26. Kremer JM, Bloom BJ, Breedveld FC, et al: The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum 2009; 60: 1895-1905.
27. Wachsmann P, Lamprecht A: Polymeric nanoparticles for the selective therapy of inflammatory bowel disease. Methods Enzymol 2012; 508: 377-397.
28. Vermeire S, Rutgeerts P, D'haens G, et al: A phase 2a randomized placebo-controlled double-blind multi-center dose escalation study to evaluate the safety, tolerability, pharmacodynamics and efficacy of AG011 in patients with moderately active ulcerative colitis. DDW 2010;46.
29. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241. (Pubitemid 40139240)